众生药业(002317) - 2026年3月25日投资者关系活动记录表

Group 1: Partnership and Licensing Agreement - The partnership between Zhongsheng Ruichuang and Qilu Pharmaceutical involves a licensing agreement for the RAY1225 injection, signed on January 16, 2026, allowing Qilu to produce and commercialize the product in China [1] - Zhongsheng Ruichuang will receive an upfront payment of RMB 200 million and potential milestone payments totaling up to RMB 800 million based on development and commercialization progress [3] - After the first commercial sale of the licensed product, Zhongsheng Ruichuang is entitled to a double-digit percentage of net sales in the licensed regions [3] Group 2: Innovation Drug Pipeline - Zhongsheng Ruichuang focuses on innovative drug development, particularly in metabolic and respiratory diseases, with two drugs already approved for market and several others in clinical trials [2] - The ZSP1601 tablet targets metabolic dysfunction-related fatty liver disease (MASH) and has shown significant efficacy in reducing liver inflammation markers in completed clinical trials [5] - RAY1225 injection, a dual agonist for GLP-1 and GIP receptors, is in Phase III trials for treating obesity and type 2 diabetes, demonstrating promising efficacy and safety [11][12] Group 3: Clinical Trials and Research - RAY1225 injection has completed Phase II trials with positive results, showing lower rates of gastrointestinal adverse reactions and hypoglycemia compared to existing treatments [11] - Ongoing Phase III trials for RAY1225 include studies for obesity, type 2 diabetes, and newly approved indications for metabolic-associated fatty liver disease and obesity-related obstructive sleep apnea [12] - The company is also developing innovative drugs for respiratory diseases, including a candidate for RSV infections, which is currently in preclinical research [8] Group 4: Financial Performance and Projections - The company projects a net profit of RMB 260 million to RMB 310 million for 2025, representing a year-on-year growth of 186.91% to 203.62% [14] - Excluding non-recurring gains and losses, the expected net profit is RMB 270 million to RMB 320 million, indicating a growth of 203.72% to 222.93% [14] - The financial growth is attributed to the successful launch of innovative drugs and a strategic focus on metabolic and respiratory disease treatments [14]